**Genetic dissection of a major haplotype associated with autoimmune disease, FcγR2b and FcγR3 act additively**

Daniëlle Vaartjes1, Dorota Klaczkowska1, Mark S Cragg2, Kutty Selva Nandakumar1,3, Liselotte Bäckdahl1, and Rikard Holmdahl1,3,#

1Division of Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden

2Antibody and Vaccine Group, Centre for Cancer Immunology, University of Southampton Faculty of Medicine, Southampton, UK

3SMU-KI United Medical Inflammation Center, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China

# Corresponding author

Rikard Holmdahl, MD, PhD, Division of Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institute, 171 77 Stockholm, Sweden, Telephone: +46-(0) 8-52484607, Email: rikard.holmdahl@ki.se

**Abstract**

A haplotype with tightly linked FcγR genes is known to be a major locus controlling immune responses and autoimmune diseases. Here, we splitted a congenic fragment (*Cia9*), derived from the NOD mouse, with different FcγR genes to study its effect on the immune response and on arthritis. Congenic *Cia9k* mice, compared to *Cia9i*,did not carry NOD.Q Fc**γ**R3, resulting in gene and protein expression differences between the genotypes for Fc**γ**R2b and Fc**γ**R3. We found that arthritis development was regulated by both genes, without impacting anti-collagen type II (CII) antibody secretion, and that macrophage mediated phagocytosis was directly correlated to Fc**γ**R3 expression. In conclusion, we positioned Fc**γ**R2b and Fc**γ**R3 to be disease regulatory and showed that their genetic polymorphisms independently and additively control innate immune cell activation and arthritis.

**Introduction**

The aetiology of chronic autoimmune diseases, such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), are polygenic diseases with numerous loci, each with small effects. However, a tightly linked region including the low affinity Fc gamma receptor genes (FcγRs) has shown clear importance [1, 2].

Linkage analyses in mouse models have revealed a major regulatory effect from a locus on chromosome 1 containing low affinity FcγR genes, associated with both antibody production and disease severity [3, 4]. However, identification of the underlying gene variants has so far been unsuccessful. The problem with this region on chromosome 1 is its high density of polymorphic genes in both mice and humans, of which many genes can have potential importance for the regulation of chronic inflammation [5, 6]. Despite the strong genetic association to autoimmune diseases in this region, no specific FcγR encoded polymorphisms have been identified as causative. Instead, the autoimmune disease regulatory function of FcγRs has been mostly studied using different knockout (KO) mouse models, which has led to some confusion. One problem has been linked genes from embryonic stem (ES) cells, as shown for FcγR2b KO mice, where the surrounding genes rather than *FcγR2b* regulate immune response [6-8]. Effects from genetic manipulation can be seen even when syngenic ES cells are used [9], which makes it difficult to mimic the naturally selected polymorphism that could regulate disease. Analyzing the individual effect from this composite set of highly polymorphic genes can therefore better be assessed in a more biological setting through natural polymorphisms by genetic mapping of phenotypic associations to relevant inflammatory disorders [5, 10-12].

Previous studies pinpointed the *Cia9* locus on chromosome 1 as being the major locus besides the MHC region to be associated with collagen-induced arthritis (CIA) [3]. CIA is the classical model for RA and is caused by well-defined type II collagen (CII) specific T and B cells [13]. The association of *Cia9* with arthritis was confirmed using a genome-wide mouse heterogeneous stock analysis, with contribution of eight inbred mouse strains [14, 15]. CIA severity and the levels of anti-CII antibodies were significantly increased in a B10.Q mouse with a NOD-derived *Cia9* congenic fragment, which included the FcγR locus [3].

To dissect the FcR confining locus, we have established four informative overlapping sub-congenic *Cia9* strains (*Cia9b, Cia9c, Cia9i* and *Cia9k*). We found that arthritis susceptibility was indeed controlled by the FcγR gene cluster, and that *FcγR2b* and *FcγR3* genes additively control inflammatory responses and arthritis.

**Results**

**Congenic mapping of *Cia9* identified the arthritis regulatory region to a <1Mb fragment**

We have previously shown that a chromosome 1 congenic locus (*Cia9*, 10 Mb in length) from NOD mice introgressed onto the B10.Q background mediates increased susceptibility to CIA [3, 15]. To identify the underlying loci, we further refined the locus and established four overlapping *Cia9* sub-congenic mouse strains (*Cia9b, Cia9c, Cia9i* and *Cia9k*).

The *Cia9b* fragment covers the region above the FcγR gene cluster, whereas *Cia9c* covers the region below the FcγR gene cluster and contains several genes from the signalling lymphycyte activation molecule (SLAM) family, in which polymorphisms have been shown important in maintaining tolerance in lupus [6, 10]. The *Cia9i* fragment contains the highly polymorphic NOD-derived FcγR gene cluster, consisting of *FcγR2b*, *FcγR4* and *FcγR3*. The smaller *Cia9k* fragment harbours NOD *FcγR2b* and *FcγR4* alleles (**Figure 1**).

We then tested which of the recombinant congenic fragments conferred the arthritis susceptibility seen in the original *Cia9* fragment by using the T and B cell dependent CIA model, as well as the T and B cell independent collagen antibody induced arthritis (CAIA) model [16, 17]. No differences in arthritis development were observed between *Cia9b* or *Cia9c* congenic mice and WT mice (**Supporting Figure 1**), restricting the disease-regulating interval to less than 1 Mb of the *Cia9* locus, i.e. the Cia9i congenic containing the FcγR cluster. After screening a high number of meiosis, we obtained a recombination within the FcγR gene cluster, excluding the NOD *FcγR3* allele from the fragment (*Cia9k),* (**Figure 1**). To investigate the role of the different Fc**γ**Rs in arthritis development, CIA was induced in WT, *Cia9i, Cia9k,* FcγR2b KO and FcγR3 KO mice (**Figure 2**). In agreement with previous studies, Fc**γ**R2b KO mice developed severe arthritis, whereas Fc**γ**R3 KO mice were completely resistant [18-21]. Due to disease severity, FcγR2b KO mice had to be sacrificed before the second injection with CII. Compared to WT mice, *Cia9i* congenic mice developed more severe arthritis with an earlier disease onset. The arthritis severity of *Cia9k* mice was milder than *Cia9i* mice, but more severe compared to WT. Analysis of anti-CII Ig and IgG isotype antibody levels in serum at day 21 and 57 after immunization showed no significant differences. The levels of anti-CII Ig, IgG1 and IgG2b were elevated in serum from *FcγR2b* KO mice, but this was related to arthritis severity rather than a direct effect on the B cell response.

In summary, mice carrying the NOD-derived *FcγR* gene cluster (*Cia9i*) or a part of the *FcγR* gene cluster (*Cia9k*) were more susceptible to CIA arthritis disease development compared to WT mice. No differences in antibody levels were observed. Therefore, these results show that FcγR2b and FcγR3 act in concert to determine the magnitude of inflammatory effector cell responses.

**Conserved haplotypes in the *FcγR* region**

Aiming to study variations in a multiple genome comparison across the *FcγR* genes, public data from the Welcome Trust mouse genome project was assessed that consists of 30 common laboratory strains, including the reference genome (C57BL/6J), and 7 wild mouse strains [22, 23]. A total of 4020 SNPs was found in the *FcγR* region (170.9-171.07) that differed between the 37 strains. *Mus Spretus* and *Mus Castaneus* were the strains that differed the most, as expected, since they are distant from *Mus Musculus* strains. In fact, 1920 out of the 4020 SNPs were unique to either *Mus Spretus* or *Mus Castaneus* or were only shared by the two. Looking closer at the remaining 2100 SNPs in the *FcγR* region, 1239 SNPs (of which 9 are non-synonymous coding) separated the 35 strains into two distinct haplotype regions covering *FcγR2b* and *FcγR4* (**Supporting** **Table 1**). 12 mouse strains, including C57BL/10J, shared haplotype I derived from the *M. musculus molossinus* (MOLF/EiJ)*,* with the reference genome. The *M. musculus musculus derived* haplotype, haplotype II, was shared by 22 mouse strains including NOD and 4 wild mouse strains (**Supporting Table 1**). In the 6 laboratory strains carrying alleles from haplotype I upstream of *Fc****γ****R3*, a recombination has occurred with a change to haplotype II: the BALBc, CBA, two DBA strains and two B57 strains, suggesting that the haplotype polymorphism was selected in the wild mouse population. This suggests that the haplotypes, now splitted in our congenic strains, have been conserved by strong natural selection.

**Polymorphisms of the FcγR cluster regulates the inflammatory arthritis effector phase**

To examine the inflammatory and not autoimmune phase of arthritis development, we used the CAIA model. Mice with the NOD-derived *FcγR* gene cluster (*Cia9i* and *Cia9k*)were more susceptible to CAIA, as compared to WT mice (**Figure 3A,B)**. Disease development before LPS injection, causing antibody-induced joint inflammation, was elevated in *Cia9i* and *Cia9k* congenic mice compared to WT mice (**Figure 3A**). This effect was enhanced after LPS stimulation (day 7), increasing inflammatory cell infiltration.

 Interestingly, *Cia9i* mice developed arthritis with higher frequency and severity as compared with the *Cia9k* mice. To study a possible FcγR3 independent effect of the congenic fragment, we first investigated reactive oxygen species (ROS) induced phagocytosis of Daudi cells, showing a difference by the Cia9i but not the *Cia9k* fragment (**Supporting Figure 2A-D**). To investigate whether the Cia9i fragment contained other arthritis regulatory genes outside the FcγR cluster we used the FcγR independent mannan-induced psoriasis (MIP) model [24]. No differences in disease development were observed between *Cia9i* congenic and WT mice (**Supporting Figure 2E**). Thus, we conclude that there is no other major effect than the FcγR polymorphism in the congenic fragment that could explain the enhanced arthritis seen in both *Cia9i* and *Cia9k.*

**No observed effect on B cell function**

To investigate why *Cia9i* and *Cia9k* congenic mice were different in arthritis susceptibility, we analysed the immune cell populations in spleens from naïve mice but found no differences (**Supporting Figure 3**). A major candidate for the arthritis susceptibility in *Cia9* mice is the *FcγR2b* gene, which is expressed on myeloid cells and B cells, with B cells lacking expression of Fc**γ**R3. Both gene and protein expression were lower in LPSactivated CD3-CD19+ B cells *in vitro* as compared with WT B cells, whereas no differences for naïve B cells were observed(**Supporting Figure 4A-C**). To determine the ability to produce antibodies *in vitro*, we stimulated total spleen cells and MACS sorted CD3-CD19+ B cells from CIA induced mice *in vitro* with ovalbumin (OVA), LPS, CII or medium for 5 days, but no differences in anti-CII antibody production between WT and *Cia9i* mice were observed (**Supporting Figure 4D)**. Despite lower expression of Fc**γ**R2b on activated B cells from *Cia9i* and *Cia9k* mice, no differences in *in vitro* antibody production by CIA primed B cells were observed, nor could any difference in IgG antibody response after CII immunization be observed **(Figure 2C-E)**. We conclude that B cells may not be a major mediator of the *FcγR* gene cluster regulated control of arthritis development.

**Increased FcγR3 expression on *Cia9i* macrophages regulates effector function**

To determine the Fc**γ**R2b expression on macrophages, we isolated thioglycolate-elicited peritoneal macrophages (TpMFs) and analysed gene and protein expression (**Figure 4A-F)**. The *FcγR2b* gene expression was drastically reduced in TpMFs of *Cia9i* and *Cia9k* congenic mice compared to WT mice. Both *Cia9i* and *Cia9k* mice had lowerFc**γ**R2b protein expression on un-stimulated and *in vitro* LPS stimulated TpMFs. We also observed elevated gene expression of *Fc***γ***R3* on macrophages from *Cia9i* mice compared to WT. Moreover, elevated levels of Fc**γ**R3 protein were found in *Cia9i* congenic mice compared to WT and *Cia9k* mice. Furthermore, *Cia9k* mice showed lower Fc**γ**R3 protein expression on LPS stimulated macrophages *in vitro* compared to WT mice. No differences in *FcγR4* gene or protein expression levels were observed between NOD and B10.Q-derived congenics. Similar gene and protein expression differences of the individual Fc**γ**Rs between genotypes were found on naïve macrophages (**Supporting Figure 5**).

To determine how the observed Fc**γ**R protein expression affects Fc**γ**R mediated function on macrophages, we used a phagocytosis model. It is known that binding of activating Fc**γ**Rs (Fc**γ**R3 and FcγR4), with pathogen-bound IgG, directly mediates clearance of the pathogen by degranulation of cytotoxic cells and phagocytosis, whereas FcγR2b inhibits the function of activating FcγRs [25]. With the *Cia9k* congenic mouse,excluding NOD FcγR3, we investigated antibody-dependent cellular phagocytosis (ADCP) of rituximab labelled Daudi cells by macrophages from WT, *Cia9i* and *Cia9k* mice, using FcγR3 KO mice as control (**Figure 4G)**. Here we show that *Cia9i* macrophages, with increased FcγR3 expression, induced more phagocytosis compared to *Cia9k* and WT macrophages (**Figure 4H)**. As expected, phagocytosis by FcγR3 KO macrophages was reduced compared to that of the congenic macrophages.

We next compared the efficiency of FcγR mediated phagocytosis *in vivo* through depletion of regulatory T (Treg) cells with the anti-CD25 antibody PC61, which is known to be dependent of FcγR3 but not FcγR2b [26]. We found that PC61 reduced the frequency of CD4+Foxp3+ Treg cells in peripheral blood in WT, *Cia9i, Cia9k* and FcγR2b KO mice, but not in FcγR3 KO mice (**Supporting Figure 6A-C**). Interestingly, the data correlates with our FcγR3 expression data for *Cia9i* macrophages. *Cia9k* mice with lower expression of FcγR, showed less efficient Treg cell depletion even when compared to WT mice. This effect was less pronounced in spleen cells 6 days after PC61 Ab. Nevertheless, both WT mice and *Cia9i* mice showed a reduction in CD4+Foxp3+ Treg cell levels compared to naïve mice. Moreover, *Cia9i* mice had fewer CD4+Foxp3+ Tregs in the spleen 6 days after PC61 Ab compared to WT and *Cia9k* mice (**Supporting Figure 6D-E**).

Taken together, *Cia9i* and *Cia9k* macrophages had decreased expression of FcγR2b compared to that of WT mice, whereas *Cia9i* macrophages showed higher expression of FcγR3, which led to increased *in vitro* and *in vivo* phagocytosis.

**NK cell function is altered by polymorphisms in FcγR3**

Since our data indicated a role for FcγR3 in the enhanced arthritis susceptibility of Cia9i mice, we next studied NK cell function, solely expressing FcγR3. We found increased *FcγR3* gene expression on CIA primed NK cells of *Cia9i* mice (**Figure 5A**). Moreover, FcγR3 protein expression was upregulated in naïve and IL2 activated NK cells from *Cia9i* mice, whereas *Cia9k* mice showed lower FcγR3 protein expression compared to WT mice (**Figure 5B,C**). IL-2 activated NK cells were used for FcγR3 mediated antibody-dependent cell cytotoxicity (ADCC) assays, with *Cia9i* NK cells showing more specific lysis at different effector/target ratios (E/T) compared to *Cia9k* and WT mice (**Figure 5D,E**). The strains had similar NK cell frequencies and secreted similar amounts of IFNγ upon PMA/ionomycin activation of NK cells (**Supporting Figure 7**).

 These data show that activated NK cells from *Cia9i* mice have upregulated FcγR3 resulting in higher NK cell functionality compared to WT and *Cia9k* mice, arguing for a role for the *FcγR3* polymorphism.

**Discussion**

The low affinity FcγR cluster is located in a conserved haplotype with a strong influence on autoimmune diseases. Here we have identified the underlying polymorphisms in this haplotype by splitting the effect of the closely linked *FcγR2b* and *FcγR3* genes in congenic mouse strains, *Cia9i* and *Cia9k*. This strategy identified both *FcγR2b* and *FcγR3* as regulators of experimental arthritis, regulating independently of each other but contributing to arthritis development additively. Moreover, both genes from the conserved haplotype of *mus musculus musculus* promoted a pro-inflammatory effect as compared to the corresponding haplotype from *mus musculus molossinus* in the B10 mouse.

The FcγRs play an essential role in inflammation and immune response and their functions are quite complex in different pathophysiologic settings. Although nomenclature differs between mice and humans, their function and binding specificities are remarkably similar [27]. The human ortologue of mouse *FcγR2b* is FcγR2b, for mouse *FcγR3* it is human FcγR2a, and mouse *FcγR4* is functionally very similar to human FcγR3a. These are highly polymorphic and associated with autoimmune diseases in humans, but in similarity with the mouse, it has been difficult to identify a disease regulatory polymorphism of *FcγR2a* and *FcγR2b* due to a high degree of linkage disequilibrium. Of particular interest is that in the mouse the three low to intermediate FcγRs (*FcγR2b*, *FcγR3* and *FcγR4*) are also strongly linked and inherited in a well-conserved haplotype. In fact, different subspecies of wild mice have different haplotypes, and inbred mouse strains have inherited different wild mouse derived haplotypes [14, 23, 28]. The haplotype polymorphisms could be older than the mouse species as has been suggested for the adjacent SLAM locus [11, 29]. The haplotype from the *Mus musculus musculus*, common on the Eurasia continent, is today carried by NOD, MRL and NZB strains, which are often more susceptible to various autoimmune diseases. In contrast, the C57.Black strains carry a haplotype from the *Mus musculus molossinus,* which naturally occurs on the Japanese islands [28, 30]. The occurrence of different haplotypes in inbred strains can help to understand the biological role of FcγR, in particular since the locus in the human population is also polymorphic. To better understand the biologic impact of this genetic information, it is necessary to isolate and study the effect of the conserved haplotype as well as to split the haplotype in order to investigate the effect of single genes.

Using *Cia9* congenic mice, we initially found that CIA severity and the levels of anti-CII IgG1 antibodies were significantly increased in *Cia9* congenic mice compared to littermate control mice, which mapped to the NOD FcγR locus [15]. However, since the *Cia9* locus consisted of more than 150 genes, the impact of NOD-derived genes other than *FcγR2b* could not be excluded. Aside from the FcγR gene cluster, *Cia9* also contained the SLAM/CD2 gene cluster, which is important in maintaining tolerance in autoimmune diseases and has been linked to lupus [6, 10]. No effect on arthritis development in congenic mice devoid of the FcγR gene cluster was observed, ruling out the role of the big SLAM/CD2 gene cluster in disease development, and the disease regulatory gene(s) were isolated to the *FcγR* region. A split recombination within the region showed that the *FcγR2b* and *FcγR3* genes jointly and additively cause the effect on arthritis. However, we cannot exclude an influence of additional genes within these small fragments. Luan *et al.* [31] described several effects contrasting to the present data but these variabilities are most likely dependent on the older data being based on a very large (25 cM) congenic fragment containing many other immune regulatory genes.

With the recombination between the *FcγR2b* and the *FcγR3* loci, we were able to study the single effect of FcγR2b and the combined effect of FcγR2b and FcγR3 on inflammatory responses. We showed that the FcγR2b and FcγR3 alleles operated in concert with an additive effect and primarily controlled the inflammatory effector phase of arthritis, not the priming autoimmune phase.

To further investigate the role of polymorphic *FcγR2b* and *FcγR3*, FcγR-dependent functions on B cells, NK cells and macrophages were studied. Impaired FcγR2bexpression in B cells in mice has been shown to influence antibody production in an antigen-independent manner [32]. Despite lower expression of FcγR2b on *Cia9i* and *Cia9k in vitro* activated B cells, no significant differences in anti-CII antibody secretion were observed. In contrast, the increased expression of FcγR3 derived from the NOD allele are likely to play a role in arthritis and showed a more pronounced phagocytosis *in vitro* and *in vivo*.

Nevertheless, despite the dramatic reduction of the arthritis prone congenic fragment there are still some additional genes in the FcγR gene cluster flanking region that might impact downstream functions. This has been indicated by the altered NK cell killing function in the *Cia9k* mice with an isolated NOD derived *FcγR2b* allele. Whereas the specific lysis by *Cia9i* and WT NK cells was linked to FcγR3 expression, that of *Cia9k* NK cells was not. Since FcγR3 expression in *Cia9k* NK cells was slightly reduced compared to WT NK cells, we expected lower or equal NK cell mediated lysis. Interestingly though, specific lysis by *Cia9k* NK cells was lower than that of *Cia9i* NK cells, but increased compared to that of WT NK cells. This implies possible involvement of other linked genes within the congenic fragment. The only gene within the *Cia9k* fragment that has been associated with NK cell-medicated cytotoxicity is the activating transcription factor 6 (Atf6) [33]. It is possible that without NOD.Q FcγR3, NOD.Q Atf6 still controls cytotoxicity. Nonetheless, with our congenic mice, we were able to study the independent and additive effect of FcγR2b and FcγR3 on inflammation. Our congenic mice could provide a more physiological setting to study FcγR function.

In summary, we show that it is the additive effect of genetic polymorphisms in *FcγR2b* and *FcγR3* that regulate inflammation most likely due to natural haplotype selection. Moreover, we show an important role of FcγR3 polymorphism on macrophage effector functions.

**Materials and Methods**

***Mice***

Mice were bred and kept at the Karolinska Institute in Stockholm, Sweden (a specific pathogenic free unit with intraventilated cages). We used the 10-Mb *Cia9* congenic fragment [15], to generate the sub-congenic fragments derived from NOD on to the B10.Q background (Fig 1). FcγR2b knockout (FcγR2bKO) [34] and FcγR3 knockout (FcγR3KO) mice [35], generated by gene targeting in 129-derived ES cells and backcrossed for more than ten generations to C57BL/6.J (B6), were obtained from Jackson Laboratory. They were further backcrossed into B10.Q background for more than ten generations in the MIR animal house and were used as experimental controls for variousassays. Genotyping was performed using markers shown in **Supporting Table 2**. Haplotype variation analysis in the genomic region (170.9-171.07Mbp) that harbours FcγR2b, FcγR4 and FcγR3 is based on 4020 SNPs found in the Welcome Trust mouse genome project database (Welcome Sanger Institute, UK), comparing sequencing-data from 37 different mouse genomes, including the reference genome C57BL/6J [22].

All experimental animal procedures were approved by the local ethics committees and were performed using B10.Q wild type littermate control mice (WT). All experiments were performed in a blinded manner with age- and sex-matched groups randomly distributed in cages. Unless stated otherwise, 10-12 weeks old male mice were used for *in vivo* experiments. Animal model experiments, including serologic measurement, were performed following earlier described protocols for CIA [15], CAIA [17] and MIP [24].

***Cells and antibodies***

The RMA T leukaemia cell line, used for NK cell mediated killing, was provided by Dr. M. Johansson (Karolinska Institute, Stockholm, Sweden) and the Daudi human B cell lymphoma cell line was provided by Dr. N. Nagy (MTC, Karolinska Institute, Stockholm, Sweden). The following antibodies were purchased from BD Biosciences (San Jose, CA) or Biolegend (San Diego, CA) and were used for analysis on a LSR-II flow cytometer (BD Biosciences): anti-CD45 (30-F11), -CD3 (145-2C11), -TCRβ (H57-597), -CD4 (H129.19), -CD8 (53-6.7), -CD19 (6D5), -CD45R/B220 (RA3-6B2), -NK1.1 (PK136), -NKp46 (29A1.4), -CD25 (PC61.5), -CD11b (M1/70), F4/80 (BM8), -CD11c (HL3), -GR-1 (RB6-8C5), -IFNγ (R46A2). Antibodies to iNOS (eBR2a) and Foxp3 (FJK-16S) were from eBioscience (San Diego, CA). The FITC-conjugated anti-mouse FcγR antibodies: anti-FcγR2b (AT130-2), -FcγR3 (AT154-2) and -FcγR4 (AT137), were generated in Southampton as previously described [36]), and were used at 10 μg/ml, 20 μg/ml and 10 μg/ml, respectively. Viability of the cells was determined with LIVE/DEAD fixable near-IR or violet dead cell stain kit (Invitrogen, Carlsbad, CA). Cancer cells were labelled with CellTrace CFSE or CellTrace Violet cell proliferation kit (Invitrogen, Carlsbad, CA). Data analysis was performed using the FlowJo software (TreeStar).

***Quantitative real-time PCR***

Total RNA was extracted using Trizol and the PureLink RNA Mini Kit (Ambion, Thermo Fisher Scientific, Waltham, MA, Life Technologies, Inc., Foster City, CA). RNA was reverse transcribed to cDNA using the High Capacity cDNA Reverse Transcription Kit (ABI Applied Biosystems, Foster City, CA). Quantitative real-time PCR (qRT-PCR) was performed on a Bio-Rad CFX96 System (Hercules, CA, USA) using TaqMan™ according to the manufacturer’s protocol. TaqMan® Gene Expression Assays (Thermo Fisher Scientific) for FcγR2b (Mm00438875\_m1 FAM), FcγR3 (Mm00438882-m1 FAM, primers/probe spanning exon2-3), FcγR3-1 (Mm01290524-m1 FAM, primers/probe spanning exon1-2), FcγR4 (Mm00519988\_m1 FAM) and the housekeeping genes Actin-β (Mm00607939\_s1 VIC) and GAPDH (Mm99999915\_g1 VIC) were used. The relative expression of each FcγR gene was determined after normalization to both housekeeping genes using the ΔΔCt method.

***B cell analysis***

Spleens were harvested and processed into single cell suspensions and B cells enriched by positive selection through CD19 microbeads according to the manufacturer’s protocol (MACS, Miltenyi Biotec, Bergisch Gladback, Germany). The purified B cells (CD3-CD19+) were determined to be >90% purity by flow cytometric analysis and used for culture and qRT-PCR.

Purified B cells and whole splenocytes were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Gibco, Thermo Fisher) supplemented with 50 U/ml penicillin, 50 mg/ml streptomycin, 10% HI fetal bovine serum, 50 uM β-mercaptoethanol and 10 mM HEPES buffer [complete DMEM] in the presence of 10 uM LPS, 10 uM CII, 10 uM ovalbumin (OVA) or medium alone. Cells were stimulated for 5 days in 5% CO2 at 37°C and anti-CII Ab production was detected by ELISA using HRP conjugated anti-kappa mAb as described above.

FcγR2b protein expression was determined on CD3-CD19+ or CD3-CD45R+ cells, on total spleen cells and purified B cells, from naïve *Cia9i*, *Cia9k* and WT mice, using flow cytometry analysis of FITC conjugated anti-FcγR2b (AT130-2, 10 μg/ml). Expression was measured as the median fluorescence intensity (MFI). Cells were stimulated with LPS for 20 hours, as described above, or left un-stimulated. FcγR2b KO mice were used as control. FcγR2b gene expression was determined on purified B cells and LPS stimulated B cells using qRT-PCR as well.

***Macrophage analysis***

Macrophages were collected by peritoneal lavage or differentiated from bone marrow cells. Naïve mice were injected i.p. with 1 ml 3-4% Brewer’s thioglycollate (Difco, BD) and peritoneal lavage was taken 4-5 days after. For qRT-PCR, cells were allowed to adhere to the surface of culture plates for 1-2 hours in DMEM supplemented with 50 U/ml penicillin, 50 μg/ml streptomycin and 10% HI FCS. Non-adherent cells were washed away and the adherent cells were treated with Trizol for RNA extraction. The adherent cells consisted of more than 90% F4/80+CD11b+ cells, confirmed by flow cytometry analysis.

For bone marrow derived macrophages (BMM), femurs were flushed and cells were cultured at 1.25x105 cells/ml in complete DMEM containing M-CSF for 7 days in 5% CO2 at 37°C. All cells were F4/80+CD11b+. Thioglycollate-elicited macrophages (TpMFs) and BMMs were used for flow cytometry analysis of FcγR proteins and for antibody-dependent cellular phagocytosis (ADCP). For ADCP, cells were cultured in DMEM, 10% FCS at 37°C, 5% CO2 and allowed to adhere ON.

Peritoneal cells were cultured in complete DMEM with or without 1 μg/ml LPS for 20 hours at 37°C, 5% CO2. Macrophages were stained with FITC-conjugated anti-mouse FcγR2b (AT130-2), FcγR3 (AT154-2) or FcγR4 (AT137) antibodies on F4/80+CD11b+ pMQs and analysed on a LSR-II flow cytometer (BD Biosciences). Expression was measured as the MFI for each FcγR, using FcγR2b KO and FcγR3 KO mice as a control for FcγR2b and FcγR3 expression, respectively. Oxidative burst assays were performed as earlier described [9].

***Antibody-dependent cellular phagocytosis (ADCP)***

ADCP was determined by flow cytometry. Macrophages were seeded at 5x104 cells/well into 96-well plates ON. Target Daudi cells were labelled with 5 μM CellTrace™ CFSE for 5 minutes at 37°C and quenched with FCS for 5 minutes at room temperature. Cells were washed twice with pre-warmed culture medium and resuspended in culture medium. Labelled Daudi cells were added to the macrophages at a 5/1 E/T ratio with or without rituximab (RTX) (provided by Inger Gjertsson, Rheumatology Unit, Sahlgrenska hospital, Göteborg, Sweden) at 1 μg/ml for 4 hours in 5% CO2 at 37°C. After 4 hours, cells were stained with F4/80 and CD11b and analysed on a LSR-II flow cytometer (BD Biosciences). ADCP was defined as the percentage of macrophages that had phagocytized. Phagocytosis was calculated as the percentage macrophages (CFSE+ CD11b+) among total target cells (CFSE+) per sample with and without RTX, and was normalized using the no RTX sample as negative control: (RTX sample – no RTX control) / (100% – no RTX control) \* 100%.

***NK cell culture***

NK cells for qRT-PCR were isolated from spleens of CIA induced *Cia9i* and WT mice. Non-NK cells were labelled with a cocktail of biotin-conjugated antibodies and anti-biotin microbeads from the MACS NK cell isolation kit II, leaving unlabelled NK cells.

To activate NK cells, splenocytes from naïve *Cia9i, Cia9k*, WT and FcγR3 KO mice were cultured for 4-7 days in complete α-MEM (containing 50 U/ml penicillin, 50 mg/ml streptomycin, 50 μM β-ME, 10 mM HEPES, 1 mM sodium pyruvate, 2 mM L-glutamine, and 10% HI FCS) supplemented with human rIL-2 (1000 U/ml; PeproTech) in 7% CO2 at 37°C [37]. These cells were used as effector cells in antibody-dependent cell-mediated cytotoxicity (ADCC) assays.

FcγR3 protein expression was assessed on CD3-NKp46+ naïve spleen cells and IL2 stimulated splenocytes, using flow cytometry analysis of FITC conjugated anti-FcγR3 (AT154-2, 20 μg/ml). Expression was measured as the MFI. FcγR3 KO mice were used as control.

***Antibody-dependent cell-mediated cytotoxicity (ADCC) by NK cells***

RMA cells were labelled with 5 μM CellTrace™ CFSE or CellTrace™ Violet (CTV) as described above. Labelled RMA cells were used as target cells at 5x103 cells per well in 96-well round bottom plates and pre-incubated with 5 μg/ml anti-Thy1.2 (clone 30-H12, BD) for 10 minutes at 37°C, and washed with complete α-MEM. NK effector cells were added to the wells containing RMA cells at effector/target (E/T) ratios 4/1, 11/1, 33/1 and 100/1 and incubated at 37°C for 4 hours [37]. To determine the background cytotoxicity, culture medium instead of anti-Thy1.2 was added as negative control. As positive control, target cells were heated for 30 minutes at 45°C [38]. ADCC was determined by flow cytometry in an LSR-II instrument (Becton Dickinson, USA). Cells were labelled with a fixable viability dye and NK cell (CD3-NKp46+) markers. Specific lysis was calculated with the number of tumor target cells killed per sample using the following formula: (experimental sample – negative control) / (positive control – negative control) \* 100%.

***In vivo regulatory T cell depletion***

CD25+ regulatory T (Treg) cells were depleted *in vivo* using PC61.5 Ab [26, 39]. One day before Treg cell depletion, *Cia9i, Cia9k,* WT, FcγR2b KO and FcγR3 KO mice were bled by tail bleeding to establish their baseline CD4+Foxp3+ T cell population. At day 0, mice were injected i.p. with 250 μg anti-CD25 (PC61.5) mAb. Blood was collected at day 1 and day 3 after PC61 Ab to determine the frequency of CD4+Foxp3+ T cells. At day 3, mice were given a second injection of 250 μg PC61. Peripheral blood and spleens were collected at day 6 after PC61 Ab and analysed by LSR II for TCRβ+/ CD4+Foxp3+ cells.

***Statistical analysis***

GraphPad Prism software (San Diego, CA, USA) was used for statistical analysis. Arthritis severity and incidence between the groups of animals were analyzed using Two-way ANOVA with Tukey’s multiple comparison and the Fisher’s exact test (and Chi-Square test when comparing to FcγR2b KO mice) respectively. For all *in vitro* experiments the Mann-Whitney U test was used when comparing data from two groups. Significance was considered when P<0.05 for a 95% confidence interval.

**Acknowledgments**

We would like to thank Dr. Michael Förster for help with the *Cia9* mice, Dr. Ia Khmaladze for help with the hybridomas, Dr. Inger Gjertsson for providing us with rituximab, Dr. Maria Johansson for their RMA cell line, Dr. Naomi Nagy for their Daudi cell lines, and the personnel of the animal facility (MIR) at KI for their excellent animal care.

This work was supported by grants from Marie Curie Fellowship Network (Osteoimmune, EU FP7-MC-ITN-289150), by the Swedish Research Council, Ehrling Persson Science foundation, Knut and Alice Wallenberg Foundation and the EU IMI project RTCure.

**Disclosures**

The authors declare that they have no competing interest.

**References**

1 **Franke, L., el Bannoudi, H., Jansen, D. T., Kok, K., Trynka, G., Diogo, D., Swertz, M., Fransen, K., Knevel, R., Gutierrez-Achury, J., Arlestig, L., Greenberg, J. D., Kremer, J., Pappas, D. A., Kanterakis, A., Weersma, R. K., van der Helm-van Mil, A. H., Guryev, V., Rantapaa-Dahlqvist, S., Gregersen, P. K., Plenge, R. M., Wijmenga, C., Huizinga, T. W., Ioan-Facsinay, A., Toes, R. E. and Zhernakova, A.,** Association analysis of copy numbers of FC-gamma receptor genes for rheumatoid arthritis and other immune-mediated phenotypes. *Eur J Hum Genet* 2016. **24**: 263-270.

2 **Gillis, C., Gouel-Cheron, A., Jonsson, F. and Bruhns, P.,** Contribution of Human FcgammaRs to Disease with Evidence from Human Polymorphisms and Transgenic Animal Studies. *Front Immunol* 2014. **5**: 254.

3 **Johansson, Å. C. M., Sundler, M., Kjellen, P., Johannesson, M., Cook, A., Lindqvist, A. K., Nakken, B., Bolstad, A. I., Jonsson, R., Alarcon-Riquelme, M. and Holmdahl, R.,** Genetic control of collagen-induced arthritis in a cross with NOD and C57BL/10 mice is dependent on gene regions encoding complement factor 5 and FcgammaRIIb and is not associated with loci controlling diabetes. *Eur J Immunol* 2001. **31**: 1847-1856.

4 **Jiang, Y., Hirose, S., Sanokawa-Akakura, R., Abe, M., Mi, X., Li, N., Miura, Y., Shirai, J., Zhang, D., Hamano, Y. and Shirai, T.,** Genetically determined aberrant down-regulation of FcgammaRIIB1 in germinal center B cells associated with hyper-IgG and IgG autoantibodies in murine systemic lupus erythematosus. *Int Immunol* 1999. **11**: 1685-1691.

5 **Morel, L., Blenman, K. R., Croker, B. P. and Wakeland, E. K.,** The major murine systemic lupus erythematosus susceptibility locus, Sle1, is a cluster of functionally related genes. *Proc Natl Acad Sci U S A* 2001. **98**: 1787-1792.

6 **Wandstrat, A. E., Nguyen, C., Limaye, N., Chan, A. Y., Subramanian, S., Tian, X. H., Yim, Y. S., Pertsemlidis, A., Garner, H. R., Jr., Morel, L. and Wakeland, E. K.,** Association of extensive polymorphisms in the SLAM/CD2 gene cluster with murine lupus. *Immunity* 2004. **21**: 769-780.

7 **Sato-Hayashizaki, A., Ohtsuji, M., Lin, Q., Hou, R., Ohtsuji, N., Nishikawa, K., Tsurui, H., Sudo, K., Ono, M., Izui, S., Shirai, T., Takai, T., Nishimura, H. and Hirose, S.,** Presumptive role of 129 strain-derived Sle16 locus in rheumatoid arthritis in a new mouse model with Fcgamma receptor type IIb-deficient C57BL/6 genetic background. *Arthritis Rheum* 2011. **63**: 2930-2938.

8 **Boross, P., Arandhara, V. L., Martin-Ramirez, J., Santiago-Raber, M. L., Carlucci, F., Flierman, R., van der Kaa, J., Breukel, C., Claassens, J. W., Camps, M., Lubberts, E., Salvatori, D., Rastaldi, M. P., Ossendorp, F., Daha, M. R., Cook, H. T., Izui, S., Botto, M. and Verbeek, J. S.,** The inhibiting Fc receptor for IgG, FcgammaRIIB, is a modifier of autoimmune susceptibility. *J Immunol* 2011. **187**: 1304-1313.

9 **Sareila, O., Hagert, C., Rantakari, P., Poutanen, M. and Holmdahl, R.,** Direct Comparison of a Natural Loss-Of-Function Single Nucleotide Polymorphism with a Targeted Deletion in the Ncf1 Gene Reveals Different Phenotypes. *PLoS One* 2015. **10**: e0141974.

10 **Morel, L., Rudofsky, U. H., Longmate, J. A., Schiffenbauer, J. and Wakeland, E. K.,** Polygenic control of susceptibility to murine systemic lupus erythematosus. *Immunity* 1994. **1**: 219-229.

11 **Limaye, N., Belobrajdic, K. A., Wandstrat, A. E., Bonhomme, F., Edwards, S. V. and Wakeland, E. K.,** Prevalence and evolutionary origins of autoimmune susceptibility alleles in natural mouse populations. *Genes Immun* 2008. **9**: 61-68.

12 **Cornall, R. J., Prins, J.-B., Todd, J. A., Pressey, A., DeLarato, N. H., Peterson, L., Wicker, L. S. and Peterson, L. B.,** Type 1 diabetes in mice is linked to the interleukin-1 receptor and Lsh/Ity/Bcg genes on chromosome 1. *Nature* 1991. **353**: 262-264.

13 **Holmdahl, R., Andersson, M., Goldschmidt, T. J., Gustafsson, K., Jansson, L. and Mo, J. A.,** Type II collagen autoimmunity in animals and provocations leading to arthritis. *Immunol Rev* 1990. **118**: 193-232.

14 **Ahlqvist, E., Ekman, D., Lindvall, T., Popovic, M., Forster, M., Hultqvist, M., Klaczkowska, D., Teneva, I., Johannesson, M., Flint, J., Valdar, W., Nandakumar, K. S. and Holmdahl, R.,** High-resolution mapping of a complex disease, a model for rheumatoid arthritis, using heterogeneous stock mice. *Hum Mol Genet* 2011. **20**: 3031-3041.

15 **Förster, M., Raposo, B., Ekman, D., Klaczkowska, D., Popovic, M., Nandakumar, K. S., Lindvall, T., Hultqvist, M., Teneva, I., Johannesson, M., Ahlqvist, E. and Holmdahl, R.,** Genetic control of antibody production during collagen-induced arthritis development in heterogeneous stock mice. *Arthritis Rheum* 2012. **64**: 3594-3603.

16 **Holmdahl, R., Rubin, K., Klareskog, L., Larsson, E. and Wigzell, H.,** Characterization of the antibody response in mice with type II collagen-induced arthritis, using monoclonal anti-type II collagen antibodies. *Arthritis Rheum* 1986. **29**: 400-410.

17 **Nandakumar, K. S., Svensson, L. and Holmdahl, R.,** Collagen type II-specific monoclonal antibody-induced arthritis in mice: description of the disease and the influence of age, sex, and genes. *Am J Pathol* 2003. **163**: 1827-1837.

18 **Yuasa, T., Kubo, S., Yoshino, T., Ujike, A., Matsumura, K., Ono, M., Ravetch, J. V. and Takai, T.,** Deletion of Fcgamma Receptor IIB Renders H-2(b) Mice Susceptible to Collagen-induced Arthritis. *J Exp Med* 1999. **189**: 187-194.

19 **Kleinau, S., Martinsson, P. and Heyman, B.,** Induction and suppression of collagen-induced arthritis is dependent on distinct fcgamma receptors. *J Exp Med* 2000. **191**: 1611-1616.

20 **Diaz de Stahl, T., Andren, M., Martinsson, P., Verbeek, J. S. and Kleinau, S.,** Expression of FcgammaRIII is required for development of collagen-induced arthritis. *Eur J Immunol* 2002. **32**: 2915-2922.

21 **Nandakumar, K. S., Andren, M., Martinsson, P., Bajtner, E., Hellstrom, S., Holmdahl, R. and Kleinau, S.,** Induction of arthritis by single monoclonal IgG anti-collagen type II antibodies and enhancement of arthritis in mice lacking inhibitory FcgammaRIIB. *Eur J Immunol* 2003. **33**: 2269-2277.

22 **Keane, T. M., Goodstadt, L., Danecek, P., White, M. A., Wong, K., Yalcin, B., Heger, A., Agam, A., Slater, G., Goodson, M., Furlotte, N. A., Eskin, E., Nellaker, C., Whitley, H., Cleak, J., Janowitz, D., Hernandez-Pliego, P., Edwards, A., Belgard, T. G., Oliver, P. L., McIntyre, R. E., Bhomra, A., Nicod, J., Gan, X., Yuan, W., van der Weyden, L., Steward, C. A., Bala, S., Stalker, J., Mott, R., Durbin, R., Jackson, I. J., Czechanski, A., Guerra-Assuncao, J. A., Donahue, L. R., Reinholdt, L. G., Payseur, B. A., Ponting, C. P., Birney, E., Flint, J. and Adams, D. J.,** Mouse genomic variation and its effect on phenotypes and gene regulation. *Nature* 2011. **477**: 289-294.

23 **Espeli, M., Clatworthy, M. R., Bokers, S., Lawlor, K. E., Cutler, A. J., Kontgen, F., Lyons, P. A. and Smith, K. G.,** Analysis of a wild mouse promoter variant reveals a novel role for FcgammaRIIb in the control of the germinal center and autoimmunity. *J Exp Med* 2012. **209**: 2307-2319.

24 **Khmaladze, I., Kelkka, T., Guerard, S., Wing, K., Pizzolla, A., Saxena, A., Lundqvist, K., Holmdahl, M., Nandakumar, K. S. and Holmdahl, R.,** Mannan induces ROS-regulated, IL-17A-dependent psoriasis arthritis-like disease in mice. *Proc Natl Acad Sci U S A* 2014. **111**: E3669-3678.

25 **Smith, K. G. and Clatworthy, M. R.,** FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. *Nat Rev Immunol* 2010. **10**: 328-343.

26 **Setiady, Y. Y., Coccia, J. A. and Park, P. U.,** In vivo depletion of CD4+FOXP3+ Treg cells by the PC61 anti-CD25 monoclonal antibody is mediated by FcgammaRIII+ phagocytes. *Eur J Immunol* 2010. **40**: 780-786.

27 **Dekkers, G., Bentlage, A. E. H., Stegmann, T. C., Howie, H. L., Lissenberg-Thunnissen, S., Zimring, J., Rispens, T. and Vidarsson, G.,** Affinity of human IgG subclasses to mouse Fc gamma receptors. *MAbs* 2017. **9**: 767-773.

28 **Takada, T., Yoshiki, A., Obata, Y., Yamazaki, Y. and Shiroishi, T.,** NIG\_MoG: a mouse genome navigator for exploring intersubspecific genetic polymorphisms. *Mamm Genome* 2015. **26**: 331-337.

29 **Valdar, W., Solberg, L. C., Gauguier, D., Burnett, S., Klenerman, P., Cookson, W. O., Taylor, M. S., Rawlins, J. N., Mott, R. and Flint, J.,** Genome-wide genetic association of complex traits in heterogeneous stock mice. *Nat Genet* 2006. **38**: 879-887.

30 **Nunome, M., Ishimori, C., Aplin, K. P., Tsuchiya, K., Yonekawa, H., Moriwaki, K. and Suzuki, H.,** Detection of recombinant haplotypes in wild mice (Mus musculus) provides new insights into the origin of Japanese mice. *Mol Ecol* 2010. **19**: 2474-2489.

31 **Luan, J. J., Monteiro, R. C., Sautes, C., Fluteau, G., Eloy, L., Fridman, W. H., Bach, J. F. and Garchon, H. J.,** Defective Fc gamma RII gene expression in macrophages of NOD mice: genetic linkage with up-regulation of IgG1 and IgG2b in serum. *J Immunol* 1996. **157**: 4707-4716.

32 **Takai, T.,** Fc receptors and their role in immune regulation and autoimmunity. *J Clin Immunol* 2005. **25**: 1-18.

33 **Gong, J., Fang, L., Liu, R., Wang, Y., Xing, J., Chen, Y., Zhuang, R., Zhang, Y., Zhang, C., Yang, A., Zhang, X., Jin, B. and Chen, L.,** UPR decreases CD226 ligand CD155 expression and sensitivity to NK cell-mediated cytotoxicity in hepatoma cells. *Eur J Immunol* 2014. **44**: 3758-3767.

34 **Takai, T., Ono, M., Hikida, M., Ohmori, H. and Ravetch, J. V.,** Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice. *Nature* 1996. **379**: 346-349.

35 **Hazenbos, W. L., Gessner, J. E., Hofhuis, F. M., Kuipers, H., Meyer, D., Heijnen, I. A., Schmidt, R. E., Sandor, M., Capel, P. J., Daeron, M., van de Winkel, J. G. and Verbeek, J. S.,** Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc gamma RIII (CD16) deficient mice. *Immunity* 1996. **5**: 181-188.

36 **Williams, E. L., Tutt, A. L., French, R. R., Chan, H. T., Lau, B., Penfold, C. A., Mockridge, C. I., Roghanian, A., Cox, K. L., Verbeek, J. S., Glennie, M. J. and Cragg, M. S.,** Development and characterisation of monoclonal antibodies specific for the murine inhibitory FcgammaRIIB (CD32B). *Eur J Immunol* 2012. **42**: 2109-2120.

37 **Wickström, S. L., Öberg, L., Kärre, K. and Johansson, M. H.,** A genetic defect in mice that impairs missing self recognition despite evidence for normal maturation and MHC class I-dependent education of NK cells. *J Immunol* 2014. **192**: 1577-1586.

38 **Salinas-Jazmin, N., Hisaki-Itaya, E. and Velasco-Velazquez, M. A.,** A flow cytometry-based assay for the evaluation of antibody-dependent cell-mediated cytotoxicity (ADCC) in cancer cells. *Methods Mol Biol* 2014. **1165**: 241-252.

39 **Lowenthal, J. W., Corthesy, P., Tougne, C., Lees, R., MacDonald, H. R. and Nabholz, M.,** High and low affinity IL 2 receptors: analysis by IL 2 dissociation rate and reactivity with monoclonal anti-receptor antibody PC61. *J Immunol* 1985. **135**: 3988-3994.

**Figure legends**

**Figure 1 Schematic overview of the *Cia9* sub-congenic fragments compared to Fcγ2b KO mice.** The positional information of the *FcγR2b* KO mice was adapted from [7]. The locations, indicated in mega base pairs (Mb), are based on the mouse genome assembly GRCm38/mm10. The different bars represent different fragments. The borders of the congenic fragments are defined by the respective markers, and the region outside applies to the B10.Q background. *Cia9* (163.5-173), *Cia9b* (163.5-170.4), *Cia9c* (171.3-173.0), *Cia9i* (169.3-171.5), *Cia9k* (169.3-171.0). Within the *Cia9* fragment, the FcγR and SLAM/CD2 gene clusters are highlighted. The arthritis regulatory region (≤1Mb), with corresponding protein-coding genes, is indicated in red. The dashed blue line shows the recombination between *Cia9i* and *Cia9k*, identified by the corresponding SNPs (rs49184774 and rs50943911, sequenced using primer pair 1 (F: TGATTGTTGCCAGGGCTAGG, R: AATGAACCTCCTCTGCAGGC) and primer pair 2 (F: CTGCTGGGTGAAACAAAGGC, R: AGATGGCGGTACTAGGGTGT), respectively). The genes in bold are located in the *Cia9k* fragment, whereas the rest was contained within the *Cia9i* fragment.

**Figure 2 *Cia9i* congenic mice are more susceptible to collagen-induced arthritis compared to *Cia9k* mice and WT mice without differences in anti-CII antibody levels between the congenic mice.** Mice were immunized with rCII on day 0 and day 35 and were monitored macroscopically for signs of arthritis. Mean arthritis score (A) and incidence (B) of WT, *Cia9i, Cia9k,* FcγR2b KO and FcγR3 KO mice. FcγR2b KO mice had to be sacrificed on day 35 due to disease severity. At day 21 and day 57 after CIA induction, serum samples were collected to assess total Ig (C), IgG1 (D) and IgG2b (E) levels of anti-CII antibodies, correlated to arthritis development. The values between brackets (A) indicate the number of mice that developed arthritis out of the total number of animals in the experiments. Data show mean+SEM (A) or mean (B,C,D,E) and represent pooled data of two individual experiments for WT, *Cia9i* and *Cia9k* mice. Two-way ANOVA with Tukey’s multiple comparison (A), Fisher’s exact test among congenics and Chi-Square test for comparison with FcγR2b KO (B) and Mann-Whiney U test (C,D,E) were used and differences were considered statistically significant when p<0.05 for a 95% confidence interval. Different symbols indicate statistical significance between *Cia9i* and WT mice (\* p<0.05, \*\* p<0.01, \*\*\* p<0.001), *Cia9k* and WT mice (# p<0.05, ## p<0.01), *Cia9i* and *Cia9k* mice ($ p<0.05), and between FcγR2b KO mice and *Cia9i/Cia9k*/WT mice (§ p<0.05, §§ p<0.01, §§§ p<0.001, §§§§ p<0.0001). The flat lines (A,B) indicate multiple timepoints, and the connected line (A) represent the Area under the curve at day 40-56.

Figure 3 Polymorphisms in the *Cia9i* and *Cia9k* fragment exacerbate the onset and development of antibody-mediated effector phase of arthritis. Mice were injected i.v. with 4 mg of anti-CII mAbs cocktail (M2139+CIIC1+CIIC2+UL1) on day 0 and boosted with LPS i.p. on day 7. Mean arthritis score (A) and incidence (B) of WT, *Cia9i* and *Cia9k* mice. The values between brackets (A) indicate the number of mice that developed arthritis out of the total number of animals in the experiments. Data show mean+SEMand represent pooled data of two independent experiments. Two-way ANOVA with Tukey’s multiple comparison (A) and Fisher‘s exact test (B) were used and differences were considered statistically significant when p<0.05 for a 95% confidence interval. The flat lines indicate multiple timepoints. Differences between WT and *Cia9i* mice: \* p<0.05, \*\* p<0.01, \*\*\* p<0.001, \*\*\*\* p<0.0001. Differences between *Cia9i* and *Cia9k* mice: $$ p<0.01, $$$$ p<0.0001. Differences between WT and *Cia9k* mice # p< 0.05, ## p<0.01, #### p<0.0001.

**Figure 4 Fc**γ**R3 expression levels on macrophages regulate antibody-dependent cellular phagocytosis (ADCP) *in vitro*.****A-F)** Gene and protein expression of FcγR2b(A,B), FcγR3(C,D) and FcγR4(E,F) on thioglycollate-elicited peritoneal macrophages (TpMFs) (CD11b+F4/80+). **A,E)** WT n=7, *Cia9i* n=9, *Cia9k* n=9. **A)** Gene expression of *FcγR2b* on FcγR2bKO mice (n=6) was absent. **C).** *FcγR3* gene expression using primer/probe sets spanning exon boundary 2-3 (FcγR3) and 1-2 (FcγR3-1) on un-stimulated (blank; WT n=6, *Cia9i* n=8, *Cia9k* n=9) or *in vitro* LPS stimulated (grey; n=6) TpMFs. Horizontal line represents gene expression of FcγR3 KO mice (n=4). **B,D,F)** Representative histogram overlay and normalized protein expression of FcγR2b (B), FcγR3 (D) and FcγR4 (F) on un-stimulated (left) and *in vitro* LPS stimulated (right) TpMFs. **B, D)** FcγR2b (B) and FcγR3 (D) protein expression were normalized using the MFI from the respective knockout mice. WT n=6, *Cia9i* n=8, *Cia9k* n=8. **F)** Un-stimulated: WT n=10, *Cia9i* n=9, *Cia9k* n=9. LPS: WT n=11, *Cia9i* n=13, *Cia9k* n=13. **G)** ADCP as percentage of phagocytosed Daudi cells (CD11b+CFSE+) among total Daudi cells (CFSE+). Representative flow cytometry contour plots show phagocytosis of Daudi cells with (+RTX, top) and without (-RTX, bottom) rituximab by macrophages of FcγR3 KO, WT, *Cia9i* and *Cia9k* mice. **H)** Phagocytosis was normalized as mentioned in material & methods. FcγR3 KO (3 KO) n=4, WT n=6, *Cia9i* n=6, *Cia9i* n=6. The data show mean +/- SEM and represent a pool of 2 (A-E,H)and 3 (F) individual experiments. A,C,E) Gene expression data were normalized to the reference genes Actin beta and GAPDH and to samples from naïve WT mice. Mann-Whitney U test was used and differences were considered statistically significant when p<0.05 for a 95% confidence interval. \* p<0.05, \*\* p<0.01, \*\*\* p<0.001.

Figure 5 FcγR3 on NK cells regulate cytotoxicity. A) Gene expression of *FcγR3* on NK cells isolated from spleens of CIA primed WT (n=19) and *Cia9i* congenic mice (n=18) on day 28 after CIA induction. Data were normalized to the reference genes Actin beta and GAPDH and to samples from naïve WT mice. B) Representative histogram overlay of FcγR3 protein expression on CD3-NKp46+ NK cells of naïve (left) and IL2 stimulated (right) spleen cells from *Cia9k*, WT, *Cia9i* mice and FcγR3 KO mice. C) FcγR3 protein expression shown as MFI on CD3-NKp46+ NK cells of naïve or IL2 stimulated spleen cells, normalized using the MFI from FcγR3 KO mice. WT n=8, *Cia9i* n=9, *Cia9k* n=8. D) Antibody-dependent cellular cytotoxicity of RMA cells by IL2 activated NK effector cells. Percentage of killed RMA cells at effector/target ratio (E/T) 4/1 in the absence (top) and presence (bottom) of anti-Thy1.2 antibody. E) Specific lysis of RMA target cells by IL2 activated NK cells at E/T ratio 4/1, 11/1, 33/1 and 100/1, as described in Materials and Methods. FcγR3 KO mice were used as assay control. FcγR3 KO n=10, WT n=10, *Cia9i* n=10, *Cia9k* n=7. The data shown are mean +/- SEM and represent a pool of 2 (C,E)and 3 (A) independent experiments. E/T 100/1 in (E) represents 1 individual experiment. Mann-Whitney U test was used and differences were considered statistically significant when p<0.05 for a 95% confidence interval. \* p<0.05, \*\* p<0.01, \*\*\* p<0.001, \*\*\*\* p<0.0001.